// App-Quantinova.ai

TPS374 : SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.

Researchers

Presenter

  • Karyn A. Goodman

Principal Investigators

  • Rui-hua Xu

  • Ian Chau

  • Ming Huang Chen

  • Byoung Chul Cho

  • Manish A. Shah

  • Kei Muro

  • Yifan Wang

  • Mari Ichimaru

  • Qingyuan Liu

  • Luhua Wang

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

  • F. Hoffmann-La Roche Ltd., Shanghai, China

  • Genentech, Inc., South San Francisico, CA

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital, Shenzhen, China

Locations

  • United States

  • China

  • United Kingdom

  • Taiwan

  • Republic of South Korea

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT03563716

  • NCT04543617

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved